To further investigate the interactions between the tumor and immune cells in relation to treatment effects, we next compared isolated tumor cells to those stimulated with ts-immune, with or without anti–PD-1 treatment (nivolumab, as detailed in Fig. 3A). The gene discussed is PDCD1; the disease is neoplasm.